Survey shows patients wait six times longer than EU neighbours for new drugsPatients in some European countries are waiting up to six times longer for access to medicines than their neighbours, Share XSurvey shows patients wait six times longer than EU neighbours for new drugshttps://pharmaphorum.com/news/survey-shows-patients-wait-six-times-longer-than-eu-neighbours-for-new-drugs/
The unprecedented challenge of pricing a coronavirus vaccineThe optimal pricing strategy for a new vaccine involves setting a fair and sustainable price that enables the Share XThe unprecedented challenge of pricing a coronavirus vaccinehttps://pharmaphorum.com/views-analysis-market-access/the-unprecedented-challenge-of-pricing-a-coronavirus-vaccine/
Gilead’s remdesivir could be $7.7bn blockbuster – analystAn influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying Share XGilead’s remdesivir could be $7.7bn blockbuster – analysthttps://pharmaphorum.com/news/gileads-remdesivir-could-be-7-7bn-blockbuster-analyst/
‘Delusional’ Shkreli refused prison release to fight coronavirusMartin Shkreli, the pharma CEO once branded as America’s most hated man has been denied release from prison after a Share X‘Delusional’ Shkreli refused prison release to fight coronavirushttps://pharmaphorum.com/news/delusional-shkreli-refused-prison-release-to-fight-coronavirus/
Shares in Vertex jump on overnight success of CF triple therapyShares in US pharma Vertex were up sharply in premarket trading after its newly-launched cystic fibrosis triple therapy attained blockbuster status Share XShares in Vertex jump on overnight success of CF triple therapyhttps://pharmaphorum.com/news/shares-in-vertex-jump-on-overnight-success-of-cf-triple-therapy/
Daiichi Sankyo: pharma needs to become NHS ‘experts’If pharma wants to help the NHS improve outcomes, it needs to do so through a true partnership Share XDaiichi Sankyo: pharma needs to become NHS ‘experts’https://pharmaphorum.com/views-analysis-market-access/daiichi-sankyo-pharma-needs-to-become-nhs-experts/
Pharma bad boy Shkreli asks for prison release to fight COVID-19Pharma bad boy Martin Shkreli has asked authorities to let him out of prison, saying that he could Share XPharma bad boy Shkreli asks for prison release to fight COVID-19https://pharmaphorum.com/news/pharma-bad-boy-shkreli-asks-for-prison-release-to-fight-covid-19/
Current pharma model “not sustainable” during COVID-19, says Daiichi’s UK leadAt eyeforpharma Daiichi Sankyo’s Manuel Reiberg spoke about why the industry should look to make drugs more affordable Share XCurrent pharma model “not sustainable” during COVID-19, says Daiichi’s UK leadhttps://pharmaphorum.com/news/current-pharma-model-not-sustainable-during-covid-19-says-daiichis-uk-lead/
Gilead rescinds orphan status request for COVID-19 drugGilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over Share XGilead rescinds orphan status request for COVID-19 drughttps://pharmaphorum.com/news/gilead-rescinds-orphan-status-request-for-covid-19-drug/
